Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Literal federal measure citations: H.R. 1227, S. 475, H.R. 1518
2026 · 2nd Quarter (Apr 1 - June 30)
VERTEX PHARMACEUTICALS
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 18, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Client
- VERTEX PHARMACEUTICALS
- Filing UUID
- 8f9fc860-2043-4abc-9471-ea681d9eb2de
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to coverage of opioid alternatives.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.